JP5324921B2 - 抗癌剤としてのデメチルペンクロメジン類似体とその使用 - Google Patents

抗癌剤としてのデメチルペンクロメジン類似体とその使用 Download PDF

Info

Publication number
JP5324921B2
JP5324921B2 JP2008545766A JP2008545766A JP5324921B2 JP 5324921 B2 JP5324921 B2 JP 5324921B2 JP 2008545766 A JP2008545766 A JP 2008545766A JP 2008545766 A JP2008545766 A JP 2008545766A JP 5324921 B2 JP5324921 B2 JP 5324921B2
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
compound
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008545766A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519344A (ja
JP2009519344A5 (https=
Inventor
リー ロイ モーガン
Original Assignee
デック−テク インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デック−テク インコーポレーティッド filed Critical デック−テク インコーポレーティッド
Publication of JP2009519344A publication Critical patent/JP2009519344A/ja
Publication of JP2009519344A5 publication Critical patent/JP2009519344A5/ja
Application granted granted Critical
Publication of JP5324921B2 publication Critical patent/JP5324921B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2008545766A 2005-12-13 2006-12-12 抗癌剤としてのデメチルペンクロメジン類似体とその使用 Active JP5324921B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75021105P 2005-12-13 2005-12-13
US60/750,211 2005-12-13
PCT/US2006/047526 WO2007070568A2 (en) 2005-12-13 2006-12-12 Demethylpenclomedine analogs and their use as anticancer agents

Publications (3)

Publication Number Publication Date
JP2009519344A JP2009519344A (ja) 2009-05-14
JP2009519344A5 JP2009519344A5 (https=) 2010-01-28
JP5324921B2 true JP5324921B2 (ja) 2013-10-23

Family

ID=38163494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545766A Active JP5324921B2 (ja) 2005-12-13 2006-12-12 抗癌剤としてのデメチルペンクロメジン類似体とその使用

Country Status (6)

Country Link
US (5) US8124596B2 (https=)
EP (1) EP1981850B1 (https=)
JP (1) JP5324921B2 (https=)
AU (1) AU2006326506B9 (https=)
CA (1) CA2632618C (https=)
WO (1) WO2007070568A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578341A2 (en) 2000-10-11 2005-09-28 Tularik Inc. Modulation of ccr4 function
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
WO2018187414A1 (en) * 2017-04-05 2018-10-11 The Regents Of The University Of California Inhibitors of mtor-rictor interactions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4717726A (en) 1986-09-10 1988-01-05 The Dow Chemical Company 3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine having anti-tumor activity
US6235761B1 (en) 1996-06-03 2001-05-22 Neil Hartman Compound, composition and method for treating cancer
WO2000043009A1 (en) * 1999-01-21 2000-07-27 Southern Research Institute Pyridine compounds, use and preparation thereof
HK1041648B (en) 1999-01-21 2011-01-14 南方研究所 Acyl derivatives of 4-demethylpenclomedine, use thereof and preparation thereof
US7122563B2 (en) 2005-02-01 2006-10-17 Southern Research Institute Derivatives of 4-demethylpenclomedine, use thereof and preparation thereof

Also Published As

Publication number Publication date
US9422241B2 (en) 2016-08-23
EP1981850B1 (en) 2017-03-22
WO2007070568A3 (en) 2007-11-08
US9884051B2 (en) 2018-02-06
US8124596B2 (en) 2012-02-28
WO2007070568A2 (en) 2007-06-21
US20090197844A1 (en) 2009-08-06
AU2006326506A2 (en) 2008-07-31
CA2632618C (en) 2014-04-22
AU2006326506B9 (en) 2012-11-15
US20200375964A1 (en) 2020-12-03
US20120177634A1 (en) 2012-07-12
AU2006326506B2 (en) 2012-05-17
JP2009519344A (ja) 2009-05-14
CA2632618A1 (en) 2007-06-21
AU2006326506A1 (en) 2007-06-21
US20160354354A1 (en) 2016-12-08
US20180117022A1 (en) 2018-05-03
EP1981850A2 (en) 2008-10-22
US10772878B2 (en) 2020-09-15

Similar Documents

Publication Publication Date Title
ES2252512T3 (es) Combinaciones antineoplasticas.
CN107921051A (zh) 抑制精氨酸酶活性的组合物和方法
KR102811484B1 (ko) 치료 덴드리머
PT2097381E (pt) Mono-hidrato de 4-[4-({[4-cloro-3-(trifluorometil)- fenil)]-carbamoíl}-amino)-3-fluorofenoxi]-n-metilpiridina- 2-carboxamida
CN107708686B (zh) 氧杂二环庚烷前药
JP2018513130A (ja) Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用
CN112654626A (zh) 化合物及其用途
US20200375964A1 (en) Demethylpenclomedine analogs and their use as anti-cancer agents
CN109922834B (zh) 用于治疗癌症的卟啉化合物和组合物
WO2016130271A1 (en) Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors
CN105131039B (zh) 一种喜树碱类磷脂化合物、其药物组合物及应用
JP2019513812A (ja) 化学療法の改善
TWI501972B (zh) 異磷醯胺芥之鹽及其類似物
CN117157281B (zh) 1,2,4,5-四噁烷化合物的靶向递送及其用途
RU2697551C2 (ru) Новые производные peg
CN113993515B (zh) 使用藏红花酸治疗实体肿瘤的方法
JP2002363076A (ja) フマギロール誘導体を用いる腫瘍の治療方法
HK40008068A (en) Porphyrin compounds and compositions useful for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121003

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130719

R150 Certificate of patent or registration of utility model

Ref document number: 5324921

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250